Drug Profile
SP 1000
Alternative Names: Cholesterol reducer; SP-1000Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Georgetown University
- Developer Samaritan Pharmaceuticals
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA
- 03 Apr 2009 SP 1000 is still in active development
- 09 May 2007 SP 1000 is still in active development